RE:RE:RE:RE:RE:Pfizer response to questions on M&A -> add value to companyAs a result of Pfizer's US$11.6 Billion acquisition, Biohaven became a wholly-owned subsidiary of Pfizer and is now raising capital to continue its operation. This development can serve as a roadmap on how ONCY can continue contributing to the development of pelareorep in multiple cancer, in combination with multiple I/O agents, in multiple indications, associated with the treatment of multiple unmet needs in liquid and solid tumor cancers.